Drug Profile
Research programme: monoclonal antibody biosimilars - Turgut Ilac
Latest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Turgut Ilac
- Developer Merck KGaA; Turgut Ilac
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-small cell lung cancer; Rheumatoid arthritis
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for research development in Non-small-cell-lung-cancer in Turkey (Parenteral)
- 28 Nov 2019 No recent reports of development identified for research development in Rheumatoid-arthritis in Turkey (Parenteral)
- 22 Oct 2015 Turgut Ilac and Merck Millipore collaborates to develop biosimilars for Non-small cell lung cancer and Rheumatoid arthritis